Previous close | 30.30 |
Open | 32.64 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 31.21 - 32.64 |
52-week range | 23.45 - 37.91 |
Volume | |
Avg. volume | 21,247 |
Market cap | 61.733B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 46.84 |
EPS (TTM) | 0.68 |
Earnings date | N/A |
Forward dividend & yield | 0.39 (1.22%) |
Ex-dividend date | 27 Sept 2024 |
1y target est | 36.01 |
AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.
Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.